ArticleFrontiers in immunology2025
Global, regional, and national burden of tuberculosis due to smoking, 1990-2021: analysis for the Global Burden of Disease study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Global, regional, and national burdens of MDR-TB attributable to smoking from 1990 to 2021 with a prediction from 2022 to 2050.Frontiers in public health · 2025Article
- Applying Multiple Analyses to Quantify Changes in the Global, Regional, and National Burden of Tuberculosis From 1990 to 2021 and the Forecast Until 2035.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Article
- The global burden of tuberculosis attributable to diet high in processed meat from 1990 to 2021: findings from the Global Burden of Disease Study 2021.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis invading the lungs and other organs, which is a serious threat to human life and health. Recent studies have shown that smoking is an important risk factor for the development of TB and advances the progression of TB through multiple mechanisms that affect the body's immune function. Methods: A multidimensional analytical approach was taken to gain a comprehensive understanding of the burden of disease. First, the burden of TB due to smoking (Deaths, DALYs, YLDs, and YLLs) from 1990-2021 was conducted. And then, differences in the burden of disease in 2021 were explored across gender, age, SDI regions, GBD regions and countries. In addition, decomposition analysis was performed to understand the influencing factors of disease burden. Finally, ARIMA and ES models were used to predict trends in disease burden from 2022-2050. Results: Globally, the number of cases and ASR of TB due to smoking have decreased over time. The burden of disease is heaviest in the middle-aged male population and is much higher than in women. The burden is higher in regions with lower levels of SDI than in those with higher levels of SDI. Australasia has the lowest burden, while India is the country with the highest burden. Projections show a general downward trend in the number of disease burdens from 2022 to 2050, but there is still a need to develop the right strategies to meet the challenges of disease. Conclusions: Smoking as an independent risk factor for several chronic diseases, this study focuses on the burden of TB due to smoking. Although the results show that the burden situation is decreasing year by year, the state and society still need to increase the publicity of science, raise the awareness of the disease among the public, and develop public health programs to deal with the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.